Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Department of Obstetrics and Gynecology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
Front Immunol. 2024 Aug 13;15:1410018. doi: 10.3389/fimmu.2024.1410018. eCollection 2024.
Ovarian cancer is currently the second most common malignant tumor among gynecological cancers worldwide, primarily due to challenges in early diagnosis, high recurrence rates, and resistance to existing treatments. Current therapeutic options are inadequate for addressing the needs of ovarian cancer patients. Ferroptosis, a novel form of regulated cell death with demonstrated tumor-suppressive properties, has gained increasing attention in ovarian malignancy research. A growing body of evidence suggests that ferroptosis plays a significant role in the onset, progression, and incidence of ovarian cancer. Additionally, it has been found that immunotherapy, an emerging frontier in tumor treatment, synergizes with ferroptosis in the context of ovarian cancer. Consequently, ferroptosis is likely to become a critical target in the treatment of ovarian cancer.
卵巢癌是目前全球妇科癌症中第二常见的恶性肿瘤，主要是由于早期诊断困难、高复发率和对现有治疗方法的耐药性。目前的治疗选择不足以满足卵巢癌患者的需求。铁死亡是一种新型的受调控的细胞死亡方式，具有肿瘤抑制特性，在卵巢恶性肿瘤研究中受到越来越多的关注。越来越多的证据表明，铁死亡在卵巢癌的发生、发展和发生中起重要作用。此外，研究发现，免疫疗法作为肿瘤治疗的一个新兴领域，在卵巢癌中与铁死亡协同作用。因此，铁死亡可能成为治疗卵巢癌的一个关键靶点。
